Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeloMATCH Substudy: Azacitidine, Venetoclax, and Quizartinib vs Standard Therapy in FLT3-ITD Mutant AML
NCT07862517Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2027
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of azacitidine, venetoclax in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07862517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862517.